Navigation Links
3-Drug Combo Reduces Nausea After Chemo
Date:5/11/2009

Study finds adding casopitant mesylate to regimen cuts side effects

MONDAY, May 11 (HealthDay News) -- The addition of the drug casopitant mesylate (CM) to the conventional two-drug regimen of dexamethasone and ondansetron greatly reduces chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly emetogenic chemotherapy (HEC), a new study concludes.

HEC is used to treat many types of solid tumor cancers, including colorectal and pancreatic cancer. Drugs such as dexamethasone and ondansetron are effective in reducing CINV in the first 24 hours after chemotherapy but only provide moderate relief during the delayed phase (24 to 120 hours after chemotherapy).

The phase 3 study included 810 patients who were receiving dexamethasone and ondansetron after undergoing HEC. They were randomly selected to also receive either a placebo (269 patients), a single 150-milligram oral dose of CM (271), or three-day intravenous plus oral CM (90-mg intravenous on the first day plus 50-mg oral on the second and third days).

The study found that 86 percent of patients in the single oral CM group and 80 percent of those in the intravenous plus oral CM group achieved a complete response (no vomiting, retching or use of rescue medications) for the first 120 hours after their first cycle of HEC treatment, compared with 66 percent of patients in the placebo group.

"A three-drug regimen including a single oral dose or three-day intravenous plus oral regimen of casopitant mesylate plus dexamethasone and ondansetron significantly reduced CINV events in patients receiving HEC compared with a two-drug regimen of dexamethasone and ondansetron," wrote Steven Grunberg, a professor at the University of Vermont, Burlington, and colleagues.

The study appears online and in the June print edition of The Lancet Oncology.

More information

The U.S. National Cancer Institute has more about managing chemotherapy-related nausea and vomiting.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, May 10, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. 3-drug combination extremely promising as first-line therapy for multiple myeloma
2. 3-Drug Combo Improves Advanced Pancreatic Cancer Outcomes
3. 3-drug chemotherapy combination increases organ preservation in patients with larynx cancer
4. Radiation and drug combo helps boost efficacy of lung cancer treatment
5. Aerobic, Weight Training Combo Best Against Diabetes
6. New antibiotic drug combo to speed up treatment of tuberculosis
7. Drug Combo Helps Fight Marfan Syndrome
8. Drug Combo Blocks Pain Without Impairing Movement
9. Two-Drug Combo Fights Brain Tumors
10. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
11. Drug Combo Boosts Multiple Myeloma Survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
3-Drug Combo Reduces Nausea After Chemo
(Date:3/27/2017)... ... 2017 , ... According to the American Cancer Society , the average ... 95%. Once the cancer spreads to other organs, bones, or lymph nodes, however, the ... avoid this latter group, tune in to Lifestyle Magazine on April 9, ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... agreement to resolve the pending litigation between itself and 1800 Vending DBA Healthy ... Utah). , “I am thrilled to announce that we have now reached a ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading provider of ... products to the Deaf Seniors of America Conference, April 4-7 at the Hotel Westin ... knowledgeable ASL friendly staff from Harris Communications and to try out the newest assistive ...
(Date:3/24/2017)... Hatboro, Pennsylvania (PRWEB) , ... March 24, 2017 ... ... and recycling solutions for contaminated soil, dredged material, and hazardous and non-hazardous materials ... headquartered in Allentown, Pennsylvania. This acquisition will add four additional processing facilities ...
(Date:3/24/2017)... ... , ... Digital Scientists, a software innovation lab specializing in web design and ... South Carolina location. The lab has set up shop at the renowned NEXT ... South Carolina clients for years from our office here in Atlanta,” explains Digital Scientists’ ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017  GenomeDx Biosciences today announced that six ... Decipher® Prostate Cancer Classifier tests will be presented at ... (EAU) Congress held March 24 to 28, 2017 in ... Congress is Europe,s largest urological ... the urological field. The abstract titled "Muscle ...
(Date:3/24/2017)... DALLAS , March 23, 2017  HealthMine surveys ... January 2017 revealed that health plan members want help ... reason to stay engaged in their health, 2) help ... an integrated platform for health and 5) relevant, real-time ... outcomes and lowering healthcare costs. ...
(Date:3/24/2017)... 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today disclosed terms ... Sheet (the "Definitive Financing") it entered into on ... stockholders, who are referred to in the Definitive ... filed with the Securities and Exchange Commission.   ...
Breaking Medicine Technology: